SUPPLEMENTAL MATERIAL

Supplemental Figure 1. A) RAPID-axSpA trial design: imaging sub-study, B) Patient disposition in the imaging set of the RAPID-axSpA trial to Week 96



*MRI readings.



*All patients received allocated treatment.

Supplemental Figure 2. A) Baseline Berlin (spine) scores stratified by presence or absence of SI joint inflammation at baseline, B) baseline SPARCC SI joint scores stratified by presence or absence of spinal inflammation at baseline, in all CZP patients (n=99)



Supplemental Figure 3. Summary of patients achieving clinical and MRI remission at Week 96 of the RAPID-axSpA study, for patients in the imaging set



[a] Of patients with SPARCC SI joint ≥2 at baseline (N); [b] Of patients with Berlin spine >2 at baseline (N); Of patients with SPARCC SI joint ≥2 and Berlin spine >2 at baseline (N). Observed data; N numbers represent the number of patients remaining in the study at Week 96

Supplemental Figure 4. Tables evaluating associations between clinical remission and MRI inflammation at Week 96 of the RAPID-axSpA trial for A) r-axSpA, and B) nr-axSpA patients included in the imaging sub-study

A) r-axSpA

SI joints

		Clinical Remission (ASDAS <1.3)	
		Yes N=21; 27.6%	**No** N=55; 72.4%
Absence of SI Joint Inflammation (SPARCC <2)	**Yes**	**81.0%** (n=17)	**80.0%** (n=44)
	No	**19.0%** (n=4)	**20.0%** (n=11)

Spine

		Clinical Remission (ASDAS <1.3)	
		Yes N=21; 27.3%	**No** N=56; 72.7%
Absence of Spinal Inflammation (Berlin ≤2)	**Yes**	**90.5%** (n=19)	**76.8%** (n=43)
	No	**9.5%** (n=2)	**23.2%** (n=13)

Both SI joints and spine

		Clinical Remission (ASDAS <1.3)	
		Yes N=21; 27.6%	**No** N=55; 72.4%
Absence of SI Joint and Spinal Inflammation (SPARCC <2 and Berlin ≤2)	**Yes**	**71.4%** (n=15)	**67.3%** (n=37)
	No	**28.6%** (n=6)	**32.7%** (n=18)

B) nr-axSpA

		Clinical Remission (ASDAS <1.3)	
		Yes N=20; 42.6%	**No** N=27; 57.4%
Absence of SI Joint Inflammation (SPARCC <2)	**Yes**	**45.0%** (n=9)	**77.8%** (n=21)
	No	**55.0%** (n=11)	**22.2%** (n=6)

		Clinical Remission (ASDAS <1.3)	
		Yes N=19; 40.4%	**No** N=28; 59.6%
Absence of Spinal Inflammation (Berlin ≤2)	**Yes**	**94.7%** (n=18)	**82.1%** (n=23)
	No	**5.3%** (n=1)	**17.9%** (n=5)

		Clinical Remission (ASDAS <1.3)	
		Yes N=19; 41.3%	**No** N=27; 58.7%
Absence of SI Joint and Spinal Inflammation (SPARCC <2 and Berlin ≤2)	**Yes**	**42.1%** (n=8)	**63.0%** (n=17)
	No	**57.9%** (n=11)	**37.0%** (n=10)

Supplemental Figure 5. Tables evaluating associations between clinical remission and MRI remission at Week 96 of the RAPID-axSpA trial, for patients included in the imaging sub-study with MRI inflammation at baseline

axSpA

		Clinical Remission (ASDAS <1.3)	
		Yes N=27; 37.5%	**No** N=45; 62.5%
SI Joint Remission (SPARCC <2)	**Yes**	**44.4%** (n=12)	**68.9%** (n=31)
	No	**55.6%** (n=15)	**31.1%** (n=14)

		Clinical Remission (ASDAS <1.3)	
		Yes N=17; 26.2%	**No** N=48; 73.8%
Spinal Remission (Berlin ≤2)	**Yes**	**82.4%** (n=14)	**68.8%** (n=33)
	No	**17.6%** (n=3)	**31.3%** (n=15)

r-axSpA

		Clinical Remission (ASDAS <1.3)	
		Yes N=10; 25.0%	**No** N=30; 75.0%
Absence of SI Joint Inflammation (SPARCC <2)	**Yes**	**60.0%** (n=6)	**70.0%** (n=21)
	No	**40.0%** (n=4)	**30.0%** (n=9)

		Clinical Remission (ASDAS <1.3)	
		Yes N=11; 22.4%	**No** N=38; 77.6%
Spinal Remission (Berlin ≤2)	**Yes**	**81.8%** (n=9)	**71.1%** (n=27)
	No	**18.2%** (n=2)	**28.9%** (n=11)

nr-axSpA

		Clinical Remission (ASDAS <1.3)	
		Yes N=17; 53.1%	**No** N=15; 46.9%
Absence of SI Joint Inflammation (SPARCC <2)	**Yes**	**35.3%** (n=6)	**66.7%** (n=10)
	No	**64.7%** (n=11)	**33.3%** (n=5)

		Clinical Remission (ASDAS <1.3)	
		Yes N=6; 37.5%	**No** N=10; 62.5%
Spinal Remission (Berlin ≤2)	**Yes**	**83.3%** (n=5)	**60.0%** (n=6)
	No	**16.7%** (n=1)	**40.0%** (n=4)

Supplemental Table 1. Cross-tabulation of SPARCC SI joint scores (<2/≥2) and Berlin (spine) scores (≤2/>2) at baseline for all patients in the imaging set

		SPARCC SI joint score	
		<2	≥2
Overall axSpA			
Berlin score	≤2	34 (22.5)	46 (30.5)
	>2	28 (18.5)	43 (28.5)
r-axSpA			
Berlin score	≤2	22 (23.7)	17 (18.3)
	>2	22 (23.7)	32 (34.4)
nr-axSpA			
Berlin score	≤2	12 (20.7)	29 (50.0)
	>2	6 (10.3)	11 (19.0)

Supplemental Table 2. SPARCC SI joint and Berlin spine scores in patients categorized by clinical disease activity.

	Week 96 ASDAS Disease Activity			
	Inactive ASDAS <1.3	**Moderate** ASDAS ≥1.3, <2.1	**High** ASDAS ≥2.1, <3.5	**Very High** ASDAS >3.5
SPARCC SI Joint				
AxSpA	**n=41**	**n=33**	**n=40**	**n=9**
Mean (SD)	2.4 (4.0)	2.0 (7.7)	2.2 (7.5)	0.8 (1.1)
Median (Q1–Q3)	0.5 (0.0–3.0)	0.0 (0.0–0.5)	0.5 (0.0–1.8)	0.5 (0.0–1.0)
Min, max	0, 19	0, 43	0, 48	0, 3
r-axSpA	**n=21**	**n=24**	**n=27**	**n=4**
Mean (SD)	1.0 (2.4)	0.3 (0.7)	2.6 (9.1)	1.3 (1.5)
Median (Q1–Q3)	0.0 (0.0–0.5)	0.0 (0.0–0.5)	0.0 (0.0–2.0)	1.0 (0.0–2.5)
Min, max	0, 9	0, 3	0, 48	0, 3
nr-axSpA	**n=20**	**n=9**	**n=13**	**n=5**
Mean (SD)	3.7 (4.8)	6.4 (14.2)	1.2 (1.4)	0.4 (0.4)
Median (Q1–Q3)	2.0 (0.4–4.5)	0.0 (0.0–3.5)	1.0 (0.0–1.5)	0.5 (0.0–0.5)
Min, max	0, 19	0, 43	0, 5	0, 1
Berlin Spine				
AxSpA	**n=40**	**n=35**	**n=40**	**n=9**
Mean (SD)	0.7 (1.1)	1.2 (1.9)	2.2 (3.6)	0.9 (2.3)
Median (Q1–Q3)	0.3 (0.0–1.0)	0.5 (0.0–2.0)	0.5 (0.0–2.3)	0.0 (0.0–0.5)
Min, max	0, 6	0, 8	0, 15	0, 7
r-axSpA	**n=21**	**n=25**	**n=27**	**n=4**
Mean (SD)	0.8 (1.3)	1.3 (2.1)	2.7 (4.1)	0.4 (0.5)
Median (Q1–Q3)	0.5 (0.0–1.0)	0.0 (0.0–1.5)	1.0 (0.0–3.5)	0.3 (0.0–0.8)
Min, max	0, 6	0, 8	0, 15	0, 1
nr-axSpA	**n=19**	**n=10**	**n=13**	**n=5**
Mean (SD)	0.5 (1.0)	1.2 (1.3)	1.2 (2.1)	1.4 (3.1)
Median (Q1–Q3)	0.0 (0.0–1.0)	0.8 (0.0–2.0)	0.0 (0.0–1.0)	0.0 (0.0–0.0)
Min, max	0, 4	0, 4	0, 7	0, 7

Data shown for all patients treated with CZP in the Imaging Set, including those re-randomized from placebo. Q1: 1st quartile; Q3: 3rd quartile; SD: standard deviation. Observed case.